Abstracts tagged "Adalimumab"

Abstract Number: 285 • 2014 ACR/ARHP Annual Meeting
Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Gerd Horneff¹, Hans Huppertz², Gerd Ganser³, Johannes Peter Haas⁴, Ivan Foeldvari⁵ and Kirsten Minden⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²Prof Hess Children’s Hospital, Bremen, Germany, ³Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁴German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶Epidemiology unit, German Rheumatism Research Center, Berlin, Germany
Background/Purpose Drug surveillance of biologics in juvenile patients using registries is of immense importance as patient numbers and duration in clinical trials are limited. There…
Abstract Number: 1843 • 2014 ACR/ARHP Annual Meeting
Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis
Noortje van Herwaarden¹, Aatke van der Maas¹, Michiel Minten¹, Frank H.J. van den Hoogen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Bart van den Bemt⁵ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ³Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose TNF inhibitors (TNFi) have proven to be effective in the treatment of rheumatoid arthritis (RA). They are however associated with side effects and high…
Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Gerd Horneff¹, Carol A. Wallace², Pierre Quartier³, Daniel J. Kingsbury⁴, Kirsten Minden⁵, Mareike Bereswill⁶, Vishvas Garg⁷, Hartmut Kupper⁶ and Jasmina Kalabic⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴Randall Children's Hospital at Legacy Emanuel, Portland, OR, ⁵Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…
Abstract Number: 1531 • 2014 ACR/ARHP Annual Meeting
CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry
Jose Rosas¹, Francisca Llinares-Tello², José M. Senabre-Gallego³, Carlos Santos-Ramirez⁴, Esteban Salas-Heredia³, Xavier Barber⁵, Gregorio Santos-Soler³, Juan Molina², Mario García-Carrasco⁶, Ana Pons³, Catalina Cano³ and Group Aire-MB³, ¹Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁴Rheumatology, Hospital Marina Salud, Denia, Spain, ⁵Universidad Miguel Hernández, CIO, Elche, Spain, ⁶Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose To evaluate the Cut-off level of adalimumab (ADL) and the prevalence of antibodies anti-adalimumab (anti-ADL-ab), in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS).…
Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Carol A. Wallace³, Mary Toth⁴, Ivan Foeldvari⁵, John Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Pavla Vavrincova⁹, Daniel J. Kingsbury¹⁰, Katherine Marzan¹¹, Pierre Quartier¹², Kirsten Minden¹³, Elizabeth Chalom¹, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason Dare¹⁶, Mareike Bereswill¹⁷, Hartmut Kupper¹⁷, Jasmina Kalabic¹⁷, Daniel Lovell¹⁸ and Alberto Martini¹⁹, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NC, ⁹Fakultni nemocnice v Motole, Praha, Czech Republic, ¹⁰Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹³Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁹PRINTO-IRCCS, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Frances Humby¹, Stephen Kelly¹, Angela V. Bedenbaugh², Nawab Qizilbash^3,4, Jochen Dunkel⁵, Belén SanJose³, Ignacio Mendez³, Jennifer Timoshanko⁶ and Jeyanesh Tambiah², ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²UCB Pharma, Smyrna, GA, ³OXON Epidemiology, London, United Kingdom, ⁴Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Slough, United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
Abstract Number: 1504 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Primal P. Kaur¹, Vincent Chow², Nan Zhang³, Mike Moxness⁴ and Richard Markus³, ¹Amgen, Inc., Thousand Oaks, CA, ²Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, WA, ³Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁴Clinical Immunology and BSM, Amgen, Inc., Thousand Oaks, CA
Background/Purpose Adalimumab is a recombinant IgG1 monoclonal antibody that binds to TNFα blocking its interaction with p55 and p75 cell surface receptors. ABP 501 is…
Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Francisca Llinares-Tello¹, Jose Rosas², José M. Senabre-Gallego³, Gregorio Santos-Soler³, Carlos Santos-Ramirez⁴, Esteban Salas-Heredia³, Xavier Barber⁵, Juan Molina¹, Catalina Cano³, Ana Pons³ and Group Aire-MB³, ¹Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ²Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁴Rheumatology, Hospital Marina Salud, Denia, Spain, ⁵Universidad Miguel Hernández, CIO, Elche, Spain
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…
Abstract Number: 1131 • 2014 ACR/ARHP Annual Meeting
Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis
Alla Skapenko¹, Hendrik Schulze-Koops¹, Viswanath Devanarayan², Kenneth Idler³, Feng Hong⁴, Josef Smolen⁵, Arthur Kavanaugh⁶, Hartmut Kupper⁷ and Jeffrey F. Waring³, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Bioresearch Center, Worchester, MA, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶University of California San Diego, La Jolla, CA, ⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: For patients with rheumatoid arthritis (RA) who fail to attain remission or low disease activity after 6 months of methotrexate (MTX) treatment, TNF inhibitors…
Abstract Number: 2915 • 2014 ACR/ARHP Annual Meeting
Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Marc Schmalzing¹, Frank Behrens^2,3, Eva C. Scharbatke¹, Michaela Koehm^3,4, Bianca Wittig⁵, Gerd Greger⁶, Harald Burkhardt^2,7 and Hans-Peter Tony⁸, ¹Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ³Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁴Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶AbbVie GmbH & Co KG, Wiesbaden, Germany, ⁷Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁸Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose Methotrexate (MTX) is currently the most frequently used drug in the treatment of rheumatoid arthritis (RA). MTX co-medication can improve the therapeutic benefit of…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 562 • 2014 ACR/ARHP Annual Meeting
Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy
Désirée M. van der Heijde¹, Joachim Sieper², Walter P. Maksymowych³, Dominique L. Baeten⁴, Yinglin Xia⁵, Jaclyn K. Anderson⁵ and Aileen L. Pangan⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) has been previously shown to be effective for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) patients (pts) in the ABILITY-1 trial.1 Week…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].